Australian Regulator: Don't Let New Ingredient Name Deadline Sneak Up On You
Executive Summary
The Therapeutic Goods Administration is urging companies to update their medicine labels and documentation with new ingredient names.
You may also be interested in...
Australia’s TGA Considers “Commercial Sensitivities” In Excipient Naming Proposals
The Therapeutic Goods Administration says consumers are frustrated that they cannot easily access information on excipient ingredients through existing mechanisms.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.